The Ultimate Directory on Healthcare Webinars

Explore this webinar on a peptide ligand, called molecular guidance system 5 (MGS5), targeting N-glycolylneuraminic acid (Neu5Gc)-Sialyl LewisA in cancer, enhancing early detection and advancing liposome-based immunotherapy for pancreatic cancer. Glycosylation is a post-translation modification that is commonly altered in cancer, playing fundamental roles in cell signaling, cell migration and invasion, immune modulation and metastasis. Neu5Ac-Sialyl LewisA (CA19-9), part of the Lewis blood antigen family, is a well-studied blood biomarker that is Food and Drug Administration (FDA) approved for the detection of pancreatic cancer. However, its counterpart, N-glycolylneuraminic acid (Neu5Gc)-Sialyl LewisA, is under study in human malignancies due to the inactivation of the cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMAH) gene and the absence of Neu5Gc-Sialyl LewisA specific targeting molecules. Read more... Utilizing a novel screening platform, a peptidic ligand (MGS5) was identified to selectively bind and rapidly internalize into cancer cells. Target identification and validation studies showed MGS5 to be highly specific for the Neu5Gc version of Sialyl LewisA. Utilizing MGS5 for detection, Neu5Gc-Sialyl LewisA was found to be significantly expressed in numerous cancer tissues, such as breast, liver and pancreas, with minimal staining observed across normal tissue types. Neu5Gc-Sialyl LewisA also demonstrated the ability to be used as an early detection biomarker for pancreatic cancer. Tissue samples of low-grade or high-grade pancreatic intraepithelial neoplasia (PanIN) lesions displayed a 2-fold increase in the binding of the MGS5 peptide compared to normal healthy pancreas. Read Less... This webinar will discuss a liposome-based immunotherapy (“Targeted Antigen Loaded Liposomes” TALL) that consists of three modular components: 1) pegylated stealth phospholipid layer, 2) an encapsulated synthetic immunogenic MHC class I restricted peptide derived from the measles virus and 3) MGS5 on the external surface for tumor targeting. MGS5 binds to the surface of the cancer cells via Neu5Gc-Sialyl LewisA and is subsequently internalized allowing for the internalization of the liposome and the release of the encapsulated antigenic peptide. This in turn elicits a robust immune response. TALL, in combination with an anti-programmed cell death protein 1 (PD-1) inhibitor, results in a 10-fold reduction in tumor burden in mice bearing orthotopic breast and pancreatic tumors, compared to using anti-PD-1 alone. Join this webinar to learn not only how MGS5 is a novel peptide for the detection of Neu5Gc- Sialyl LewisA, but it can also serve as a therapeutically relevant cancer targeting agent allowing for the delivery of therapeutics.

Throughout this session, we will delve into the report's key findings, providing an in-depth look at the current health status of the nation. Our experts will discuss how the effective integration of data and healthtech technology, as offered by dacadoo, can transform these insights into compelling wellness narratives and impactful strategies. This is a unique opportunity to hear firsthand how relevant and intelligently analyzed data can make a significant difference in the health and wellness sector. Join us for an informative and enriching conversation that promises to inspire and offer valuable insights into the future of digital health and life insurance.

Zero falls, that is. How can Zero be your hero? What metrics matter? What story do they tell? What story do I need them to tell? What outcomes do they impact? How do they prove ROI for my patient safety program? We're here to answer all your analytics questions…and more. Join: Chief Product Officer, Nicholas Luthy, Director of User Experience Design, Paul Rouillard, and Senior Director of Clinical Education, Nicole Shields, BSN, RN, on January 31st at 10 AM CST for a 45-minute interactive webinar on virtual patient observation analytics. We'll cover all the above with a real-time deep dive into the analytics portal. We'll share some best practices and a sneak peek of new features. Be A Hero. Get to Zero.

This webinar describes the work on vascular and Alzheimer’s dementias within the Strong Heart Study, including implementation of Community-Based Participatory Methods to recruit and examine over 1000 American Indian elders from 11 tribes across 3 regions.

In a new webinar, Manatt will explain proposed New York cybersecurity regulations and what they mean for providers, share insights to help hospitals guard against attacks, and present lessons for other states seeking to put protections in place.

Residents & Researchers: “What’s all that dust? The need for fugitive dust controls” with Stuart Batterman (University of Michigan, Environmental Health Sciences) and Simone Sagovac (Southwest Detroit Community Benefits Coalition). Moderated by Natalie Sampson (University of Michigan Dearborn). Sponsored by the Michigan Center on Lifestage Environmental Exposures and Disease (M-LEEaD) Community Engagement Core + Integrated Health Sciences Core.

Discover an informative webinar exploring patient-centered approaches shaping ophthalmology trials, uniting stakeholders for better treatments and outcomes. Clinical trials in ophthalmology require special considerations at every stage, including trial design, recruitment strategies, patient outreach and engagement, assessments and data collection and management of investigational products or devices. The key to success is putting the patients and their caregivers at the center when considering the overall approach to the trial. This panel session is fortunate to include the father of a child affected by Leber hereditary optic neuropathy (LHON) and will open with the perspective of a parent and active patient advocate. The speakers will address advances in trial design specific to rare/genetic diseases of the eye, with a focus on cell and gene therapy, the need to work collaboratively in this space to match advanced therapeutic trial design to the unique needs of investigating ocular diseases and how new perspectives on patient centricity is leading to the evolution of these trials. Join this webinar to gain insights into how sponsors, service providers, investigator sites, caregivers and patient advocacy groups can work together to accelerate the pace of bringing new treatments to these patients, for better outcomes and improved quality of life. Keywords: Clinical Trials, Rare Disease, Gene Therapy, Clinical Research, Patient-Centricity, CRO, Patient Recruitment, Cell Therapy, Eye Disease, Rare Disease Clinical Trials, Vision, Ophthalmology, Cell & Gene Therapies

This multiple-method study recently published in the European Journal of Pain provides credible explanations for the six most common diagnoses of non-traumatic knee pain. Additionally, it identified three key domains that may need to be addressed to reduce diagnostic uncertainty in adolescents suffering from pain complaints. Find out more about the study and its findings in this webinar and use the opportunity to ask questions. Here is the link: https://onlinelibrary.wiley.com/doi/full/10.1002/ejp.2210

International Pediatric Association invites you to join our webinar: “Survivorship in Childhood Cancer: Global Challenges”.

EHE Pillars in Practice: Diagnose, Treat, Prevent, Respond & Building Workforce Capacity in HIV Care and Treatment:  First Session: HIV Testing Training - focusing on innovative testing efforts to improve early diagnosisSpeaker:  Jorgette Theophilis Program Manager of HIV ServicesBrockton Neighborhood Health CenterAccreditation Statement:  This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of UMass Chan Medical School and New England AIDS Education and Training Center. The UMass Chan Medical School is accredited by the ACCME to provide continuing medical education for physicians.Credit Designation Statement: The University of Massachusetts Chan Medical School designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.Nurses: Under the auspices of the New England AIDS Education & Training Center, This offering meets the requirements for a maximum of 1.2 contact hours, as specified by the Massachusetts Board of Registration in Nursing (244-CMR 5.04). Each nurse should claim only those hours of credit that he/she actually spent in the educational activity.